Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Sapanisertib in Combination With Cabozantinib in ß-catenin-mutated Hepatocellular Carcinoma (SAPHIRE)

NCT06811116 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06811116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06811116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Sapanisertib in Combination With Cabozantinib in ß-catenin-mutated Hepatocellular Carcinoma (SAPHIRE)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 17, 2025
Completion date
August 31, 2027
Enrollment
92 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma, metastatic hepatocellular carcinoma, stage iii hepatocellular carcinoma ajcc v8, stage iv hepatocellular carcinoma ajcc v8